Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences High-Value Diagnostics
Conferences  \  Biofluid Biopsies & High-Value Diagnostics 2015  \  High-Value Diagnostics  \  Agenda  \  Klaus Lücke
RegisterLogin

Klaus Lücke's Biography


Klaus Lücke, CEO & Founder, GILUPI GmbH

Klaus Luecke brings to GILUPI more than 30 years of technical and entrepreneurial experience. Before founding GILUPI, he worked in Germany as well as in the US for Siemens AG, Bell Labs und Infineon AG. From 1999 until 2001 he was Vice President and General Manager of Infineon AG’s Business Unit in San Jose/USA.

After coming back to Germany, he founded the Infineon Technologie ORION GmbH in Duisburg. He also served as Executive Director of Infineon Technologies AG in Munich, being responsible for various Design Centers in Singapore, Munich and Düsseldorf. He studied Physics at Freie Universität Berlin, Germany.

 Klaus Lücke Image

Liquid Biopsies – Cancer Disease Profiling with Less Burden on Patients

Monday, 16 November 2015 at 17:30

Add to Calendar ▼2015-11-16 17:30:002015-11-16 18:30:00Europe/LondonLiquid Biopsies – Cancer Disease Profiling with Less Burden on PatientsSELECTBIOenquiries@selectbiosciences.com

Liquid biopsy techniques use markers found in blood such as circulating tumor cells (CTCs) for improving the diagnosis and treatment of cancer. Its’ significant advantage over highly invasive tumor biopsies is the minimal invasiveness and that it can be performed repetitively, thus being well suited for regular monitoring of disease progression and development of disease resistance following treatment.

The GILUPI CellCollector® liquid biopsy device is uniquely capable of gathering patient-specific disease information critical to the achievement of improved clinical outcomes in major therapeutic areas including oncology and cardiovascular disease. GILUPI’s novel in vivo technology has proven highly effective in disease diagnosis, treatment monitoring and drug development via provision of real time biomarker analysis and patient disease data in a minimally invasive manner.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonHigh-Value DiagnosticsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors